MetaCap

BridgeBio Pharma (BBIO) vs United Therapeutics (UTHR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

United Therapeutics (UTHR) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 16.8% versus a gain of 11.6%. Over five years, UTHR leads with a +186.5% price change compared with +92.2% for BBIO. United Therapeutics is the larger company by market cap ($23.63 billion vs $14.81 billion), about 1.6 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs +10.6%).

United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus -146.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBIO+11.63%UTHR+16.83%
+34%+13%-9%
Nov 21, 20251 yearNov 20, 2026
BBIO+78.26%UTHR+175.81%
+212%+57%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBIO versus UTHR key metrics
MetricBBIOUTHR
Share price$76.03$554.73
Market cap$14.81B$23.63B
1-day change-2.75%-0.78%
YTD return-0.60%+13.85%
1-year return+11.63%+16.83%
5-year return+92.24%+186.47%
P/E ratio (TTM)—20.94
Forward P/E—17.44
EPS (TTM)$-3.03$26.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$502.08M$3.18B
Revenue growth (YoY)+126.26%+10.61%
Net income (latest FY)$-732.94M$1.33B
Gross margin95.82%87.92%
Operating margin-104.25%46.89%
Net margin-145.98%41.94%
52-week high$93.42$614.23
52-week low$62.50$455.63
Distance from 52-week high-18.61%-9.69%
Analyst consensusstrong_buybuy
Avg. price target upside+40.73%+23.87%
Average volume2.67M702.78K
Shares outstanding194.80M42.59M
Employees1,0811,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
  • BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +10.61%).

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

About United Therapeutics

UTHR stock →

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees

BBIO vs UTHR FAQ

Which is bigger, BridgeBio Pharma or United Therapeutics?

United Therapeutics (UTHR) is larger, with a market capitalization of $23.63B compared with $14.81B for BridgeBio Pharma (BBIO).

Which stock has performed better over the past year, BBIO or UTHR?

UTHR returned +16.83% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Pharma and United Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons